April 09, 2026

Tony Hyman starts as EMBL Director General

Tony Hyman starts as EMBL Director General

Former EMBL group leader returns to lead the organisation’s six sites at a time of change and opportunity in life sciences

Tony Hyman starts as EMBL’s new Director General on 31 March 2026. Credit: Sven Döring

EMBL welcomes its new Director General, Tony Hyman, who will take up the mandate of leading EMBL’s six sites as the organisation enters its next phase.

Hyman succeeds Interim Director Ewan Birney, who assumed leadership following the death of Interim Director General Peer Bork in January. Together, they led EMBL after former Director General Edith Heard departed to become Director and Chief Executive of the Francis Crick Institute in London.

Hyman has had a long-standing relationship with EMBL, having served as a group leader and visiting senior scientist at EMBL Heidelberg from 1993 to 1999. He is also one of four founding directors of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, and holds a professorship of Molecular Biology at Technische Universität Dresden. His research focuses on the role of biological condensates and phase separation in health and disease.

“This is a moment when biology is changing rapidly,” said Hyman. “Advances in imaging, large-scale data generation, and artificial intelligence are reshaping how we study living systems. EMBL has played an important role in previous periods of change, and I look forward to working with colleagues across the organisation as it enters this next phase.”

Our latest News

discover more
bioRN is hiring: Junior Communications & Event Manager (m/f/d) (80-100%), starting January 2027 or by arrangement

bioRN is hiring: Junior Communications & Event Manager (m/f/d) (80-100%), starting January 2027 or by arrangement

Turn your passion for life sciences into stories, connections and experiences! Do you have a background in life sciences and a passion for communications? Do you enjoy creating engaging content, connecting with different audiences, and bringing ideas to life? At bioRN Life Science Cluster, we connect leading research institutions, global pharmaceutical companies, biotech start-ups and […]

CST Announces Availability of GMP-Grade CAR Linker Antibodies for CAR-T Cell Enrichment and Detection in Clinical Manufacturing and QC

CST Announces Availability of GMP-Grade CAR Linker Antibodies for CAR-T Cell Enrichment and Detection in Clinical Manufacturing and QC

Danvers, MA, USA, October 7, 2026–Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced the availability for purchase of GMP-grade recombinant monoclonal antibody conjugates targeting the G4S linker of scFv-based chimeric antigen receptors (CARs) for CAR-T cell enrichment and detection in cell therapy manufacturing […]

Wittenstein Biointelligence Prize: AwardedBacteria Produce Bioplastic; Living Nerve Cells Process Information

Wittenstein Biointelligence Prize: AwardedBacteria Produce Bioplastic; Living Nerve Cells Process Information

The Wittenstein Biointelligence Prize was awarded on Tuesday evening at the third Biointelligence Congress. Biotechnologist Moritz Bross won in the “Individual” category, while Cortical Labs was honored in the “Company” category. With this prize, the Wittenstein Foundation recognizes innovative, practical, and sustainable solutions that combine biology with information and production technology. Full Text in German […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp